Drug development event focuses on East Asia

TOKYO – Professionals from across East Asia will discuss the latest hot topics in all stages of drug development at the DIA Annual Conference in Japan for Asian New Drug Development. The event will return for its eighth year on May 22 to 23, at Sola City Hall, Ochanomizu in Tokyo. Expert speakers will share information and experiences regarding the current situation of new drug development in the emerging East Asia region, and provide advice on how to improve the value and quality of new drugs.

Sessions will focus on the latest regulatory information, early phase clinical trial, collaboration between academic organizations, regulatory inspection, regional study communications and late phase development strategy.

Other session highlights include:

> Early Phase and Regional Clinical Trials in Asia/Academia Collaboration in East Asia

> East Asian Regulatory Update on Global Clinical Trials

> Trend of GCP Inspection

> Optimal Development Strategies Based on Differences in Culture and Health Care Setting

> Effective and Efficient Communication in Asia Regional Studies

> Panel Discussions

Program chair Hidetoshi Shuto, corporate executive for Astellas Pharma Inc., said: “Drug development in East Asia has become extremely vigorous as the interests of organizations related to drug development expand. Such organizations are now not only interested in the advancement of drug development, but also the maximization of generated value and the improvement of quality in new drug development.

“In order to facilitate drug development under the revised regulations for optimal regulatory circumstances, professionals involved in drug development face various challenges. Furthermore, collaboration to work towards drug development beyond each country’s boundaries is strongly desired in this era of globalization. This conference will discuss these topics and much more.”

The 8th DIA Annual Conference in Japan for Asian New Drug Development will feature presentations on the latest regulatory trends and regional clinical trials in Asia from industry leaders and high-profile representatives from Asian regulatory authorities, including the Pharmaceuticals and Medical Devices Agency (PMDA), China Food and Drug Administration (CFDA), and the Ministry of Food and Drug Safety in Republic of Korea. Academic speakers from Japan, China and Korea will also provide their future visions of new drug development and the role of academia collaboration in East Asia.